Christina E Thaller

6506917, Jan 14, 2003

Jun 7, 1995

08/480967

Ronald M. Evans - La Jolla CA
David J. Mangelsdorf - Dallas TX
Richard A. Heyman - Encinitas CA
Marcus F. Boehm - San Diego CA
Gregor Eichele - Houston TX
Christina Thaller - Houston TX

The Salk Institute for Biological Studies - La Jolla CA

C07C 5300

554221

In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i. e. , rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

6576676, Jun 10, 2003

Jul 9, 1999

09/350648

Ronald M. Evans - La Jolla CA
David J. Mangelsdorf - Dallas TX
Richard A. Heyman - Encinitas CA
Marcus F. Boehm - San Diego CA
Gregor Eichele - Houston TX
Christina Thaller - Houston TX

The Salk Institute for Biological Studies - La Jolla CA
Baylor College of Medicine - Houston TX
Ligand Pharmaceuticals, Inc. - San Diego CA

A61K 31203

514725, 514 1

In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i. e. , rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

6992108, Jan 31, 2006

Jun 7, 1995

08/482737

Ronald M. Evans - La Jolla CA, US
David J. Mangelsdorf - Dallas TX, US
Richard A. Heyman - Encinitas CA, US
Marcus F. Boehm - San Diego CA, US
Gregor Eichele - Houston TX, US
Christina Thaller - Houston TX, US

The Salk Institute for Biological Studies - La Jolla CA
Baylor College of Medicine - Houston TX
Ligand Pharmaceuticals, Inc. - San Diego CA

A61K 31/19
A61K 31/20

514560, 514557, 514558

A method for modulating lipid metabolism in a subject by administering 9-cis retinoic acid is presented. The 9-cis retinoic acid is more specific for the retinoid X receptor than is retinoic acid.

7056954, Jun 6, 2006

Jun 10, 2003

10/458880

Ronald M. Evans - La Jolla CA, US
David J. Mangelsdorf - Duncanville TX, US
Richard A. Heyman - Encinitas CA, US
Marcus F. Boehm - San Diego CA, US
Gregor Eichele - Houston TX, US
Christina Thaller - Houston TX, US

The Salk Institute for Biological Studies - La Jolla CA
Baylor College of Medicine - Waco TX
Ligand Pharmaceuticals, Inc. - San Diego CA

A61K 31/07

514725

In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i. e. , rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

20060211768, Sep 21, 2006

Oct 21, 2005

11/256501

Ronald Evans - La Jolla CA, US
David Mangelsdorf - Duncanville TX, US
Richard Heyman - Encinitas CA, US
Marcus Boehm - San Diego CA, US
Gregor Eichele - Houston TX, US
Christina Thaller - Houston TX, US

A61K 31/203

514559000

In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

59689897, Oct 19, 1999

Jun 7, 1995

8/472817

Ronald M. Evans - La Jolla CA
David J. Mangelsdorf - Dallas TX
Richard A. Heyman - Encinitas CA
Marcus F. Boehm - San Diego CA
Gregor Eichele - Houston TX
Christina Thaller - Houston TX

The Salk Institute for Biological Studies - La Jolla CA
Baylor College of Medicine - Houston TX
Ligand Pharmaceuticals, Inc. - San Diego CA

A01N 3104
A01N 3700
A61K 3821

514725

In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i. e. , rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

59326220, Aug 3, 1999

Jun 7, 1995

8/475174

Ronald M. Evans - La Jolla CA
David J. Mangelsdorf - Dallas TX
Richard A. Heyman - Encinitas CA
Marcus F. Boehm - San Diego CA
Gregor Eichele - Houston TX
Christina Thaller - Houston TX

The Salk Institute for Biological Studies - La Jolla CA
Baylor College of Medicine - Houston TX
Ligand Pharmaceuticals, Inc. - San Diego CA

A61K 3107
C12N 506

514725

A method for modulating non-malignant skin related disorders in a subject has been demonstrated with 9-cis retinoic acid. Wrinkling, acne, keratinization, differentiation and proliferation disorders are treated by administration of 9-cis retinoic acid alone or in a pharmaceutically acceptable carrier to a subject in need thereof.